Evidence map›Paper›PMID 30553841›Full record

ArticleJournal of hepatology2019

Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.

Massimiliano Cadamuro, Simone Brivio, Joachim Mertens, Marta Vismara, Anja Moncsek, Chiara Milani, Christian Fingas, Maria Cristina Malerba, Giorgia Nardo, Luigi Dall'Olmo and 9 more

Open access · greenAbstract read
In one paragraph

Article in Journal of hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 1 pooled it
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 1 synthesis or guideline pooled it, 181 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Diagnostic and Prognostic Values of Bile Biomarkers for Malignant Biliary Stenosis.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 4 countries.

Massimiliano CadamuroDepartment of Molecular Medicine, University of Padua, Padova, Italy; International Center for Digestive Health (ICDH), University of Milan-Bicocca, Milan, Italy; School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Simone BrivioSchool of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Joachim MertensDepartment of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.
Marta VismaraSchool of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Anja MoncsekDepartment of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.
Chiara MilaniSchool of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Christian FingasDepartment of General, Visceral, and Transplantation Surgery, University Hospital Essen, Essen, Germany.
Maria Cristina MalerbaSchool of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Giorgia NardoImmunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
Luigi Dall'OlmoDepartment of Emergency and Urgency (DEU), Ulss 3 Serenissina, Mestre, Italy.
Eleonora MilaniDepartment of Molecular Medicine, University of Padua, Padova, Italy.
Valeria MariottiDepartment of Molecular Medicine, University of Padua, Padova, Italy.
Tommaso SteccaIV Department Of Surgery, Regional Center for HPB Surgery, Ca' Foncello Regional Hospital, Treviso, Italy.
Marco MassaniIV Department Of Surgery, Regional Center for HPB Surgery, Ca' Foncello Regional Hospital, Treviso, Italy.
Carlo SpirliInternational Center for Digestive Health (ICDH), University of Milan-Bicocca, Milan, Italy; Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, CT, USA.
Romina FiorottoInternational Center for Digestive Health (ICDH), University of Milan-Bicocca, Milan, Italy; Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, CT, USA.
Stefano IndraccoloImmunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
Mario StrazzaboscoInternational Center for Digestive Health (ICDH), University of Milan-Bicocca, Milan, Italy; School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, CT, USA.
Luca FabrisDepartment of Molecular Medicine, University of Padua, Padova, Italy; International Center for Digestive Health (ICDH), University of Milan-Bicocca, Milan, Italy; Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, CT, USA. Electronic address: luca.fabris@unipd.it.
University of Milano-Bicocca · ITUniversity of Padua · ITYale University · USCa' Foncello Hospital · ITIstituto Oncologico Veneto · ITUniversity Hospital of Zurich · CHEssen University Hospital · DE

Funding

Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
Epithelial Angiogenic Signaling in Polycystic Diseases of the LiverR01DK079005 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2008 to 2017
$3.5M
NIDDK NIH HHS P30 DK034989NIDDK NIH HHS R01 DK079005
6 · The paper itself

Abstract

BACKGROUND &

aimsIn cholangiocarcinoma, early metastatic spread via lymphatic vessels often precludes curative therapies. Cholangiocarcinoma invasiveness is fostered by an extensive stromal reaction, enriched in cancer-associated fibroblasts (CAFs) and lymphatic endothelial cells (LECs). Cholangiocarcinoma cells recruit and activate CAFs by secreting PDGF-D. Herein, we investigated the role of PDGF-D and liver myofibroblasts in promoting lymphangiogenesis in cholangiocarcinoma.

methodsHuman cholangiocarcinoma specimens were immunostained for podoplanin (LEC marker), α-SMA (CAF marker), VEGF-A, VEGF-C, and their cognate receptors (VEGFR2, VEGFR3). VEGF-A and VEGF-C secretion was evaluated in human fibroblasts obtained from primary sclerosing cholangitis explants. Using human LECs incubated with conditioned medium from PDGF-D-stimulated fibroblasts we assessed migration, 3D vascular assembly, transendothelial electric resistance and transendothelial migration of cholangiocarcinoma cells (EGI-1). We then studied the effects of selective CAF depletion induced by the BH3 mimetic navitoclax on LEC density and lymph node metastases in vivo.

resultsIn cholangiocarcinoma specimens, CAFs and LECs were closely adjacent. CAFs expressed VEGF-A and VEGF-C, while LECs expressed VEGFR2 and VEGFR3. Upon PDGF-D stimulation, fibroblasts secreted increased levels of VEGF-C and VEGF-A. Fibroblasts, stimulated by PDGF-D induced LEC recruitment and 3D assembly, increased LEC monolayer permeability, and promoted transendothelial EGI-1 migration. These effects were all suppressed by the PDGFRβ inhibitor, imatinib. In the rat model of cholangiocarcinoma, navitoclax-induced CAF depletion, markedly reduced lymphatic vascularization and reduced lymph node metastases.

conclusionPDGF-D stimulates VEGF-C and VEGF-A production by fibroblasts, resulting in expansion of the lymphatic vasculature and tumor cell intravasation. This critical process in the early metastasis of cholangiocarcinoma may be blocked by inducing CAF apoptosis or by inhibiting the PDGF-D-induced axis. LAY SUMMARY: Cholangiocarcinoma is a highly malignant cancer affecting the biliary tree, which is characterized by a rich stromal reaction involving a dense population of cancer-associated fibroblasts that promote early metastatic spread. Herein, we show that cholangiocarcinoma-derived PDGF-D stimulates fibroblasts to secrete vascular growth factors. Thus, targeting fibroblasts or PDGF-D-induced signals may represent an effective tool to block tumor-associated lymphangiogenesis and reduce the invasiveness of cholangiocarcinoma.

Indexed as

AnimalsBile Duct NeoplasmsCancer-Associated FibroblastsCell Line, TumorCholangiocarcinomaDisease Models, AnimalEndothelial CellsHeterograftsHumansImatinib MesylateLiverLymphangiogenesisLymphokinesMaleMiceMice, SCIDImatinib MesylateLymphokinesPDGFD protein, humanPdgfd protein, ratPDGFRB protein, humanPlatelet-Derived Growth FactorProtein Kinase InhibitorsReceptor, Platelet-Derived Growth Factor betaVascular Endothelial Growth Factor AVascular Endothelial Growth Factor CVEGFA protein, humanVEGFC protein, humanCholangiocytesLymphatic endothelial cellsTumor reactive stromaVEGF-CVEGFR3

Identifiers

PMID30553841
PMCPMC10878126
OpenAlexW2904172984

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.